
Rosella Centis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6487515/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. Presse Medicale, 2022, 51, 104112.	0.8	9
2	Clinical standards for the diagnosis, treatment and prevention of TB infection. International Journal of Tuberculosis and Lung Disease, 2022, 26, 190-205.	0.6	29
3	Drug resistant TB – latest developments in epidemiology, diagnostics and management. International Journal of Infectious Diseases, 2022, 124, S20-S25.	1.5	37
4	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. International Journal of Infectious Diseases, 2022, 124, S90-S103.	1.5	18
5	Diagnostic Accuracy of Rapid Antigen Tests for COVID-19 Detection: A Systematic Review With Meta-analysis. Frontiers in Medicine, 2022, 9, 870738.	1.2	16
6	Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts. Jornal Brasileiro De Pneumologia, 2022, 48, e20210515.	0.4	6
7	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. Jornal Brasileiro De Pneumologia, 2022, 48, e20220087.	0.4	10
8	TB and COVID-19 co-infection: rationale and aims of a global study. International Journal of Tuberculosis and Lung Disease, 2021, 25, 78-80.	0.6	22
9	TB management in the European Union/European Economic Area: a multiâ€centre survey. International Journal of Tuberculosis and Lung Disease, 2021, 25, 126-133.	0.6	1
10	Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology, 2021, 27, 151-165.	1.0	172
11	Tuberculosis and COVID-19, the new cursed duet: what differs between Brazil and Europe?. Jornal Brasileiro De Pneumologia, 2021, 47, 20210044.	0.4	15
12	Post-TB disease: a new topic for investigation—and why it matters. International Journal of Tuberculosis and Lung Disease, 2021, 25, 258-261.	0.6	6
13	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology, 2021, 27, 248-256.	1.0	18
14	The Role of Blood Gas Analysis in the Post-Acute Phase of COVID-19 Pneumonia. Archivos De Bronconeumologia, 2021, , .	0.4	4
15	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. European Respiratory Journal, 2021, 58, 2101786.	3.1	86
16	Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. Jornal Brasileiro De Pneumologia, 2021, 47, e20210076.	0.4	7
17	The definition of tuberculosis infection based on the spectrum of tuberculosis disease. Breathe, 2021, 17, 210079.	0.6	59
18	Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patients. Pulmonology, 2021, 27, 452-455.	1.0	25

#	Article	IF	CITATIONS
19	Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology, 2021, 27, 403-412.	1.0	30
20	Tuberculosis Rehabilitation and Palliative Care. , 2021, , 275-281.		0
21	Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. International Journal of Tuberculosis and Lung Disease, 2021, 25, 797-813.	0.6	78
22	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. Antibiotics, 2021, 10, 1355.	1.5	5
23	Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating. The Lancet Global Health, 2021, 9, e1628-e1629.	2.9	4
24	Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis. Journal of Asthma, 2020, 57, 1365-1371.	0.9	7
25	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. European Respiratory Journal, 2020, 55, 1901908.	3.1	11
26	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. Emerging Infectious Diseases, 2020, 26, 2709-2712.	2.0	133
27	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). Frontiers in Medicine, 2020, 7, 572485.	1.2	15
28	COVID-19 and tuberculosis—threats and opportunities. International Journal of Tuberculosis and Lung Disease, 2020, 24, 757-760.	0.6	45
29	Post-tuberculosis sequelae: the need to look beyond treatment outcome. International Journal of Tuberculosis and Lung Disease, 2020, 24, 761-762.	0.6	29
30	Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology, 2020, 26, 233-240.	1.0	178
31	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. European Respiratory Journal, 2020, 56, 2001398.	3.1	273
32	Commemorating World TB Day 2020: "lT'S TIME―— It's time to End the Global TB Epidemic. Interr Journal of Infectious Diseases, 2020, 92, S1-S4.	national 1.5	6
33	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. European Respiratory Journal, 2020, 56, 2001727.	3.1	89
34	Post tuberculosis treatment infectious complications. International Journal of Infectious Diseases, 2020, 92, S41-S45.	1.5	36
35	Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. International Journal of Infectious Diseases, 2020, 92, S10-S14.	1.5	20
36	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 2020, 92, S15-S25.	1.5	126

#	Article	IF	CITATIONS
37	Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. Applied Sciences (Switzerland), 2020, 10, 2734.	1.3	8
38	Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2020, 24, 700-705.	0.6	29
39	The need for pulmonary rehabilitation following tuberculosis treatment. International Journal of Tuberculosis and Lung Disease, 2020, 24, 720-722.	0.6	25
40	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. Journal of Infection, 2019, 78, 35-39.	1.7	30
41	Multidrug-resistant tuberculosis. Lancet, The, 2019, 394, 298.	6.3	10
42	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. European Respiratory Journal, 2019, 54, 1901522.	3.1	113
43	International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis. Jornal Brasileiro De Pneumologia, 2019, 45, e20180420.	0.4	5
44	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. International Journal of Infectious Diseases, 2019, 83, 72-76.	1.5	41
45	Recent evidence on delamanid use for rifampicin-resistant tuberculosis. Journal of Thoracic Disease, 2019, 11, S457-S460.	0.6	9
46	Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office forÂEurope. European Respiratory Journal, 2019, 53, 1900391.	3.1	81
47	Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. European Respiratory Journal, 2019, 53, 1802184.	3.1	51
48	Delamanid: does it have a role in tuberculosis treatment?. Lancet Respiratory Medicine,the, 2019, 7, 193-195.	5.2	4
49	Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals. European Respiratory Journal, 2019, 54, 1901578.	3.1	2
50	Point of care diagnostics for tuberculosis. Pulmonology, 2018, 24, 73-85.	1.0	84
51	Multi and extensively drug-resistant pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 2018, 24, 244-252.	1.2	21
52	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017Âupdate. European Respiratory Journal, 2018, 51, 1702678.	3.1	50
53	Tuberculosis, social determinants and co-morbidities (including HIV). Pulmonology, 2018, 24, 115-119.	1.0	156
54	Migration, TB control and elimination: Whom to screen and treat. Pulmonology, 2018, 24, 99-105.	1.0	19

#	Article	IF	CITATIONS
55	Tuberculosis elimination: a dream or a reality? The case of Oman. European Respiratory Journal, 2018, 51, 1702027.	3.1	18
56	Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. European Respiratory Journal, 2018, 51, 1702187.	3.1	1
57	Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico. European Respiratory Journal, 2018, 51, 1702267.	3.1	10
58	Diagnostic performances of the Xpert MTB/RIF in Brazil. Respiratory Medicine, 2018, 134, 12-15.	1.3	13
59	Eliminating tuberculosis in Latin America: making it the point. Jornal Brasileiro De Pneumologia, 2018, 44, 73-76.	0.4	10
60	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	6.3	452
61	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. European Respiratory Journal, 2018, 52, 1800934.	3.1	59
62	Tuberculosis elimination: where are we now?. European Respiratory Review, 2018, 27, 180035.	3.0	76
63	Management of tuberculosis in the European Union: a multicentre audit. , 2018, , .		0
64	Outcomes of drug-resistant TB cases undergoing bedaquiline (BQ)-treatment and adjunctive surgery. , 2018, , .		0
65	Management of extensively drug-resistant tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 237-239.	5.2	1
66	Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant Tuberculosis. Archivos De Bronconeumologia, 2017, 53, 245-250.	0.4	23
67	La diabetes se asocia con reacciones adversas graves en la tuberculosis multirresistente. Archivos De Bronconeumologia, 2017, 53, 245-250.	0.4	23
68	Breaking the barriers: Migrants and tuberculosis. Presse Medicale, 2017, 46, e5-e11.	0.8	26
69	Resistance profile of drugs composing the "shorter―regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015. European Respiratory Journal, 2017, 49, 1602309.	3.1	25
70	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. European Respiratory Journal, 2017, 49, 1700387.	3.1	233
71	World TB Day 2017: Strengthening the fight against TB. Presse Medicale, 2017, 46, e1-e4.	0.8	2
72	Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. European Respiratory Journal, 2017, 49, 1700146.	3.1	59

#	Article	IF	CITATIONS
73	Effectiveness and safety of clofazimine inÂmultidrug-resistant tuberculosis: aÂnationwide report from Brazil. European Respiratory Journal, 2017, 49, 1602445.	3.1	63
74	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 688-694.	1.1	35
75	Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?. International Journal of Infectious Diseases, 2017, 56, 30-33.	1.5	22
76	European policies in the management of tuberculosis among migrants. International Journal of Infectious Diseases, 2017, 56, 85-89.	1.5	22
77	Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data. Revista Portuguesa De Pneumologia, 2017, 23, 27-30.	0.7	11
78	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2017, 49, 1600993.	3.1	20
79	Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?. International Journal of Infectious Diseases, 2017, 65, 133-134.	1.5	3
80	Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. European Respiratory Journal, 2017, 50, 1701462.	3.1	103
81	Applicability of the shorter â€~Bangladesh regimen' in high multidrug-resistant tuberculosis settings. International Journal of Infectious Diseases, 2017, 56, 190-193.	1.5	38
82	WHO Strategies for the Management of Drug-Resistant Tuberculosis. Archivos De Bronconeumologia, 2017, 53, 95-97.	0.4	5
83	Classifying new anti-tuberculosis drugs: rationale and future perspectives. International Journal of Infectious Diseases, 2017, 56, 181-184.	1.5	82
84	Estrategias de la OMS para el tratamiento de la tuberculosis resistente. Archivos De Bronconeumologia, 2017, 53, 95-97.	0.4	6
85	Children under 5â€years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. European Respiratory Journal, 2017, 50, 1701414.	3.1	21
86	Understanding the multidrug-resistant tuberculosis epidemic in China. International Journal of Tuberculosis and Lung Disease, 2017, 21, 955-955.	0.6	1
87	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. Emerging Infectious Diseases, 2017, 23, 1718-1721.	2.0	43
88	Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. International Journal of Molecular Sciences, 2017, 18, 341.	1.8	47
89	Tuberculosis, Public Health Aspects. , 2017, , 252-266.		1
90	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. Jornal Brasileiro De Pneumologia, 2017, 43, 380-392.	0.4	26

#	Article	IF	CITATIONS
91	Cross-border collaboration for improved tuberculosis prevention and care: policies, tools and experiences. International Journal of Tuberculosis and Lung Disease, 2017, 21, 727-736.	0.6	27
92	Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. Journal of Thoracic Disease, 2017, 9, 2093-2101.	0.6	52
93	Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results. , 2017, , \cdot		Ο
94	A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium. Indian Journal of Medical Research, 2017, 145, 261-263.	0.4	0
95	Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. Journal of Thoracic Disease, 2016, 8, 2666-2671.	0.6	39
96	Surgery and pleuro-pulmonary tuberculosis: a scientific literature review. Journal of Thoracic Disease, 2016, 8, E474-E485.	0.6	45
97	Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?. Jornal Brasileiro De Pneumologia, 2016, 42, 374-385.	0.4	45
98	Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review. International Journal of Molecular Sciences, 2016, 17, 373.	1.8	75
99	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS ONE, 2016, 11, e0151724.	1.1	12
100	Crossborder travel and multidrugresistant tuberculosis (MDRTB) in Europe. Travel Medicine and Infectious Disease, 2016, 14, 588-590.	1.5	9
101	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR-ÂandÂXDR-TB. European Respiratory Journal, 2016, 47, 1758-1766.	3.1	69
102	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. European Respiratory Journal, 2016, 48, 1160-1170.	3.1	27
103	Faster for less: the new "shorter―regimen for multidrug-resistant tuberculosis. European Respiratory Journal, 2016, 48, 1503-1507.	3.1	66
104	Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil. Revista Portuguesa De Pneumologia, 2016, 22, 337-341.	0.7	11
105	Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. European Respiratory Journal, 2016, 48, 808-817.	3.1	75
106	New anti-tuberculosis drugs for special populations: a difficult-to-address issue. European Respiratory Journal, 2016, 48, 957-958.	3.1	5
107	Preventing and controlling tuberculosis among refugees in Europe: more is needed. European Respiratory Journal, 2016, 48, 272-274.	3.1	19
108	WHO recommendations for multidrug-resistant tuberculosis – Authors' reply. Lancet, The, 2016, 388, 2234-2235.	6.3	1

#	Article	IF	CITATIONS
109	Recent developments in the diagnosis and management of tuberculosis. Npj Primary Care Respiratory Medicine, 2016, 26, 16078.	1.1	58
110	Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. European Respiratory Journal, 2016, 48, 1527-1529.	3.1	28
111	WHO strategies for the programmatic management of drug-resistant tuberculosis. Expert Review of Respiratory Medicine, 2016, 10, 991-1002.	1.0	34
112	WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet, The, 2016, 387, 2486-2487.	6.3	47
113	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. European Respiratory Journal, 2016, 48, 938-943.	3.1	71
114	First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. European Respiratory Journal, 2016, 48, 935-938.	3.1	84
115	Efficacy and tolerability of ethionamide <i>versus</i> prothionamide: a systematic review. European Respiratory Journal, 2016, 48, 946-952.	3.1	25
116	Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clinical Infectious Diseases, 2016, 62, 887-895.	2.9	64
117	Recommendations for pediatric tuberculosis vaccination in Italy. Human Vaccines and Immunotherapeutics, 2016, 12, 644-650.	1.4	2
118	Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. European Respiratory Journal, 2016, 47, 664-667.	3.1	23
119	Recommendations Concerning the First-Line Treatment of Children with Tuberculosis. Paediatric Drugs, 2016, 18, 13-23.	1.3	11
120	Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees. European Respiratory Journal, 2016, 47, 1345-1347.	3.1	34
121	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. European Respiratory Journal, 2016, 47, 686-688.	3.1	17
122	Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. European Respiratory Journal, 2016, 47, 394-402.	3.1	136
123	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2016, 62, 1188.2-1190.	2.9	34
124	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 2016, 47, 1235-1243.	3.1	92
125	Tuberculosis management and determinants of recurrence. International Journal of Tuberculosis and Lung Disease, 2016, 20, 3-3.	0.6	4
126	Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. European Respiratory Journal, 2016, 47, 333-336.	3.1	64

#	Article	IF	CITATIONS
127	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis. , 2016, , .		Ο
128	Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis. , 2016, , .		0
129	Monitoring predictors of mortality: A necessary action to reach TB elimination. Revista Portuguesa De Pneumologia, 2015, 21, 295-298.	0.7	4
130	New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Research, 2015, 1, 00010-2015.	1.1	65
131	The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. European Respiratory Journal, 2015, 45, 571-574.	3.1	8
132	Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. International Journal of Infectious Diseases, 2015, 32, 101-104.	1.5	36
133	Is Europe ready to reach tuberculosis elimination? An outbreak report from Southern Italy. European Respiratory Journal, 2015, 46, 274-277.	3.1	4
134	Accelerating tuberculosis elimination in low-incidence settings: the role of genomics. European Respiratory Journal, 2015, 46, 1841-1843.	3.1	0
135	Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. European Respiratory Journal, 2015, 45, 287-289.	3.1	19
136	Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2015, 13, 305-315.	2.0	39
137	Key role of tuberculosis services funding mechanisms in tuberculosis control and elimination. European Respiratory Journal, 2015, 45, 289-291.	3.1	14
138	Tuberculosis Treatment and Drug Regimens. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a017822-a017822.	2.9	131
139	Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal. European Respiratory Journal, 2015, 45, 292-294.	3.1	16
140	Tuberculosis control in prisons: current situation and research gaps. International Journal of Infectious Diseases, 2015, 32, 111-117.	1.5	113
141	Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. International Journal of Infectious Diseases, 2015, 32, 156-160.	1.5	19
142	Universal health coverage and social support in Senegal: a comprehensive approach against tuberculosis. European Respiratory Journal, 2015, 46, 869-871.	3.1	6
143	Tuberculosis treatment and management—an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respiratory Medicine,the, 2015, 3, 220-234.	5.2	172
144	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	3.1	608

#	Article	IF	CITATIONS
145	Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review <i>versus</i> expert opinion. European Respiratory Journal, 2015, 45, 1170-1173.	3.1	15
146	Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clinical Infectious Diseases, 2015, 61, S102-S118.	2.9	74
147	Management of drug resistantTB in patients with HIV co-infection. Expert Opinion on Pharmacotherapy, 2015, 16, 2737-2750.	0.9	10
148	How to manage children who have come into contact with patients affected by tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2015, 1, 1-12.	0.6	9
149	Compassionate and optimum use of new tuberculosis drugs. Lancet Infectious Diseases, The, 2015, 15, 1131-1132.	4.6	32
150	The multidrug-resistant tuberculosis threat: old problems and new solutions. Journal of Thoracic Disease, 2015, 7, E354-60.	0.6	8
151	A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium. Journal of Thoracic Disease, 2015, 7, 1080-5.	0.6	8
152	ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases. European Respiratory Journal, 2014, 43, 286-289.	3.1	32
153	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. European Respiratory Journal, 2014, 44, 811-815.	3.1	96
154	Bacille Calmette-Guerin vaccination: the current situation in Europe. European Respiratory Journal, 2014, 43, 24-35.	3.1	33
155	Tuberculosis elimination: dream or reality? The case of Cyprus. European Respiratory Journal, 2014, 44, 543-546.	3.1	46
156	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1364-1374.	2.9	116
157	Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. European Respiratory Journal, 2014, 43, 289-292.	3.1	54
158	Tuberculosis elimination: theory and practice in Europe. European Respiratory Journal, 2014, 43, 1410-1420.	3.1	148
159	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. European Respiratory Journal, 2013, 42, 252-271.	3.1	211
160	Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. European Respiratory Journal, 2013, 42, 785-801.	3.1	163
161	Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. European Respiratory Journal, 2013, 41, 1386-1392.	3.1	145
162	Do we need a new Fleming époque: The nightmare of drug-resistant tuberculosis. International Journal of Mycobacteriology, 2013, 2, 123-125.	0.3	9

#	Article	IF	CITATIONS
163	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2013, 42, 169-179.	3.1	226
164	A case of resistance beyond extensively drug-resistant tuberculosis in Japan. European Respiratory Journal, 2013, 42, 872-873.	3.1	2
165	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. European Respiratory Journal, 2013, 42, 156-168.	3.1	346
166	Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence: Table 1–. European Respiratory Journal, 2013, 42, 288-290.	3.1	45
167	TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia. Journal of Infection in Developing Countries, 2013, 7, 289-292.	0.5	8
168	Medical treatment of pulmonary tuberculosis. , 2013, , 11-19.		1
169	Multidrug-Resistant Tuberculosis. New England Journal of Medicine, 2012, 367, 2154-2156.	13.9	10
170	On linezolid efficacy and tolerability. European Respiratory Journal, 2012, 39, 770-772.	3.1	23
171	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	3.9	430
172	Multidrug-resistant tuberculosis today. Bulletin of the World Health Organization, 2012, 90, 78-78.	1.5	19
173	TB and MDR-TB: what is new in 2012?. Breathe, 2012, 9, 100-111.	0.6	2
174	Drug-resistant tuberculosis among foreign-born persons in Italy: Table 1–. European Respiratory Journal, 2012, 40, 497-500.	3.1	20
175	Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. European Respiratory Journal, 2012, 40, 1081-1090.	3.1	99
176	Availability of anti-tuberculosis drugs in Europe: Table 1–. European Respiratory Journal, 2012, 40, 500-503.	3.1	9
177	Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy: Figure 1–. European Respiratory Journal, 2012, 39, 1263-1266.	3.1	10
178	Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?. Clinical Infectious Diseases, 2012, 54, 1379-1380.	2.9	67
179	Risk factors associated with pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 2012, 18, 233-240.	1.2	60
180	Declaration on palliative care for MDR/XDR-TB [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1418-1419.	0.6	2

#	Article	IF	CITATIONS
181	TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?. European Respiratory Journal, 2012, 39, 619-625.	3.1	74
182	European Union Standards for Tuberculosis Care. European Respiratory Journal, 2012, 39, 807-819.	3.1	188
183	Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. European Respiratory Journal, 2012, 40, 814-822.	3.1	58
184	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. European Respiratory Journal, 2012, 40, 1430-1442.	3.1	346
185	Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. European Respiratory Journal, 2012, 40, 133-142.	3.1	42
186	Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2012, 10, 1109-1115.	2.0	11
187	Epidemiology of TB. , 2012, , 14-25.		2
188	Tuberculosis. Lancet, The, 2011, 378, 57-72.	6.3	670
189	Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. European Respiratory Journal, 2011, 38, 730-733.	3.1	47
190	TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?. European Respiratory Journal, 2011, 38, 1221-1223.	3.1	52
191	Tuberculosis: an ancient and evergreen disease. European Respiratory Review, 2011, 20, 69-70.	3.0	2
192	Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. Current Opinion in Pulmonary Medicine, 2010, 16, 1.	1.2	18
193	Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Tropical Medicine and International Health, 2010, 15, 1052-1066.	1.0	62
194	Drugâ€resistant tuberculosis: Past, present, future. Respirology, 2010, 15, 413-432.	1.3	110
195	Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. European Respiratory Journal, 2010, 36, 208-211.	3.1	22
196	From the authors:. European Respiratory Journal, 2010, 35, 938-940.	3.1	4
197	Extensively drug-resistant tuberculosis: back to the future. European Respiratory Journal, 2010, 36, 475-477.	3.1	39
198	A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. European Respiratory Journal, 2009, 34, 387-393.	3.1	170

#	Article	IF	CITATIONS
199	Multidrug- and extensively drug-resistant TB in persons living with HIV. Expert Review of Respiratory Medicine, 2009, 3, 245-254.	1.0	8
200	Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2009, 64, 879-883.	1.3	10
201	Reversing the tuberculosis upwards trend: a success story in Romania. European Respiratory Journal, 2009, 33, 168-170.	3.1	13
202	MDR-TB and XDR-TB: drug resistance and treatment outcomes. European Respiratory Journal, 2009, 34, 778-779.	3.1	30
203	Consensus Not Yet Reached on Key Drugs for Extensively Drugâ€Resistant Tuberculosis Treatment. Clinical Infectious Diseases, 2009, 49, 315-316.	2.9	6
204	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal, 2009, 33, 871-881.	3.1	163
205	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. European Respiratory Journal, 2008, 31, 1155-1159.	3.1	131
206	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. Clinical Infectious Diseases, 2008, 46, 958-959.	2.9	35
207	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. European Respiratory Journal, 2008, 31, 904-905.	3.1	67
208	Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany. Emerging Infectious Diseases, 2008, 14, 1700-1706.	2.0	113
209	Tuberculosis, one disease, many faces. Monaldi Archives for Chest Disease, 2008, 69, 2-4.	0.3	7
210	Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal, 2007, 30, 623-626.	3.1	179
211	Ripped from the headlines: how can we harness communications to control TB?. European Respiratory Journal, 2007, 30, 194-198.	3.1	7
212	Multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> : epidemiology and control. Expert Review of Anti-Infective Therapy, 2007, 5, 857-871.	2.0	101
213	First tuberculosis cases in Italy resistant to all tested drugs. , 2007, 12, E070517.1.		113
214	Mycobacterium tuberculosisComplex Drug Resistance in Italy. Emerging Infectious Diseases, 2004, 10, 752-753.	2.0	7
215	Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998–2000. European Respiratory Journal, 2003, 21, 129-134.	3.1	12
216	Evaluation of tuberculosis treatment results in Italy, report 1998. Tuberculosis section of the National AIPO Study Group on Infectious Disease and the SMIRA Group. Monaldi Archives for Chest Disease, 2000, 55, 293-8.	0.3	9